Applied Health Economics and Health Policy

Article	Citations
Approaches to Incorporation of Preferences into Health Economic Models of Genomic Medicine: A Critical Interpretive Synthesis and Conceptual Framework	75
Is the Use of Unanchored Matching-Adjusted Indirect Comparison Always Superior to Naïve Indirect Comparison on Survival Outcomes? A Simulation Study	48
Australian Preferences for Prenatal Screening: A Discrete Choice Experiment Comparing Metropolitan and Rural/Regional Areas	35
Population Norms for SF-6Dv2 and EQ-5D-5L in China	33
Methods and Practical Considerations for Conducting Budget Impact Analysis for Non-Pharmaceutical Interventions	31
Developing a Framework for the Health Technology Assessment of Histology-independent Precision Oncology Therapies	30
Productivity Losses due to Health Problems Arising from COVID-19 Pandemic: A Systematic Review of Population-Level Studies Worldwide	30
Comment on: “Willingness to Pay for a COVID-19 Vaccine”	28
Effect of Competition on Generic Drug Prices	26
Financial Incentives in the Path to Recovery from the COVID-19 Pandemic	26
Does the Choice of Health Metric, DALY or QALY, Influence Conclusions of Health Economic Evaluation? A Case Study of Rotavirus Vaccine in Burundi	23
Korean Guidelines for Pharmacoeconomic Evaluations: Updates in the Third Version	23
Correction to: Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canaglifozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting	22
Using Economics to Impact Local Obesity Policy: Introducing the UK Centre for Economics of Obesity (CEO)	20
Economic Evaluations of Preventive Interventions for Dental Caries and Periodontitis: A Systematic Review	19
Cost-Utility Analysis of Major System Change in Specialist Cancer Surgery in London, England, Using Linked Patient-Level Electronic Health Records and Difference-in-Differences Analysis	19
Herd Immunity Effects in Cost-Effectiveness Analyses among Low- and Middle-Income Countries	17
A Comparative Analysis of Anticancer Drug Appraisals Including Managed Entry Agreements in South Korea and England	17
A Model-Based Estimate of the Cost-Effectiveness Threshold in Germany	16
Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in Sweden	15
Cost-Effectiveness of Anti-retroviral Adherence Interventions for People Living with HIV: A Systematic Review of Decision Analytical Models	15
An Economic Model for Estimating Trial Costs with an Application to Placebo Surgery Trials	14
Systematic Review of the Psychometric Performance of Generic Childhood Multi-attribute Utility Instruments	14
Cost Effectiveness of Denosumab for Secondary Prevention of Osteoporotic Fractures Among Postmenopausal Women in China: An Individual-Level Simulation Analysis	14
Values in Modelling: Video Series Development and Evaluation Survey	13

Health Interventions May Have Divergent Impacts on Health and Economic Equity: A Case Study of the Community-Based Hypertension Improvement Project in Ghana	13
Projected Impact on Labour Productivity Costs of Cancer-Related Premature Mortality in Europe 2018–2040	13
Simplified Methods for Modelling Dependent Parameters in Health Economic Evaluations: A Tutorial	13
Review and Assessment of Policy Options for Improving Access to Combination Therapies in Oncology in Europe	13
Measurement of Health-Related Quality of Life from Conception to Postpartum Using the EQ-5D-5L Among a National Sample of US Pregnant and Postpartum Adults	13
Evidence Synthesis and Linkage for Modelling the Cost-Effectiveness of Diagnostic Tests: Preliminary Good Practice Recommendations	12
Cost-Utility Analysis of TNF-α Inhibitors, B Cell Inhibitors, and JAK Inhibitors Versus csDMARDs for Rheumatoid Arthritis Treatment	12
A Contingent Valuation Study for Use in Valuing Public Goods with Health Externalities: The Case of Street Pianos	11
Deterministic and Probabilistic Analysis of a Simple Markov Model: How Different Could They Be?	11
Cost-Effectiveness of Perinatal Depression Screening: A Scoping Review	11
Authors’ Reply to Gandjour: “10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?”	11
Rationing in an Era of Multiple Tight Constraints: Is Cost-Utility Analysis Still Fit for Purpose?	11
Are Drug Novelty Characteristics Associated With Greater Health Benefits?	11
The Gift of Time, How Do I Want to Spend It? Exploring Preferences for Time Allocation Among Women with and without a Breast Cancer Diagnosis	11
A structured process for the validation of a decision-analytic model: application to a cost-effectiveness model for risk-stratified national breast screening	10
Cost-Effective and Sustainable Drug Use in Hospitals: A Systematic and Practice-Based Approach	10
Correction: Economic Evaluations of Robotic-Assisted Surgery: Methods, Challenges and Opportunities	10
Assessing the Direct Impact of Death on Discrete Choice Experiment Utilities	10
COVID-19 Vaccine Demand and Financial Incentives	9
A Systematic Review of the Costs Relating to Non-pharmaceutical Interventions Against Infectious Disease Outbreaks	9
Cost-Effectiveness Analysis of Stockholm 3 Testing Compared to PSA as the Primary Blood Test in the Prostate Cancer Diagnostic Pathway: A Decision Tree Approach	8
Young People’s Preferences for Web-Based Mental Health Interventions for Managing Anxiety and Depression: A Discrete Choice Experiment	8
Acknowledgement to Referees	8
Approaches to Measure Efficiency in Primary Care: A Systematic Literature Review	8
Incidence of Catastrophic Health Expenditure and Its Determinants in Cancer Patients: A Systematic Review and Meta-analysis	8
Correction to: Incidence of Catastrophic Health Expenditure and Its Determinants in Cancer Patients: A Systematic Review and Meta‑analysis	8
Machine Learning-Assisted Health Economics and Policy Reviews: A Comparative Assessment	8
Value and Price of Multi-indication Cancer Drugs in the USA, Germany, France, England, Canada, Australia, and Scotland	8
A Systematic Review on Economic Evaluation Studies of Diagnostic and Therapeutic Interventions in the Middle East and North Africa	8
Therapy, Pills and Unmet Needs for Financial Reasons: Socioeconomic Inequalities and Inequities in Access to Mental Health Care in Spain 2014–2020	8
Correction to: The Cost Effectiveness of Taxation of Sugary Foods and Beverages: A Systematic Review of Economic Evaluations	7
Cost Effectiveness of Allogeneic Umbilical Cord Blood-Derived Mesenchymal Stem Cells in Patients with Knee Osteoarthritis	7
National Methodological Guidelines to Conduct Budget Impact Analysis for Health Technology Assessment in India	7
Is There Broad-Based Support in High-Income Countries for COVID-19 Vaccine Donation? Evidence from Seven Countries	7
Willingness to Pay for National Health Insurance: A Contingent Valuation Study Among Patients Visiting Public Hospitals in Melaka, Malaysia	7
A Review of Current Approaches to Evaluating and Reimbursing New Medicines in a Subset of OECD Countries	7
Preferred Attributes of Care Pathways for Obstructive Sleep Apnoea from the Perspective of Diagnosed Patients and High-Risk Individuals: A Discrete Choice Experiment	7
‘What You See is All There is’: The Importance of Heuristics in Cost-Benefit Analysis (CBA) and Social Return on Investment (SROI) in the Evaluation of Public Health Interventions	7
The Effects of School Closures on COVID-19: A Cross-Country Panel Analysis	7
Population-Based Testing for Undiagnosed Hepatitis C: A Systematic Review of Economic Evaluations	7
Information Asymmetry in Hospitals: Evidence of the Lack of Cost Awareness in Clinicians	6
Applications of Behavioral Economics to Pharmaceutical Policymaking: A Scoping Review with Implications for Best-Value Biological Medicines	6
Cost Effectiveness of Deep Brain Stimulation for Parkinson’s Disease: A Systematic Review	6
Psychometric Evaluation of the PedsQL GCS and CHU9D in Australian Children and Adolescents with Common Chronic Health Conditions	6
Adding a Gene Expression Profile Test to Aid Differential Diagnosis and Treatment in Aggressive Large B-Cell Lymphoma: An Early Exploratory Economic Evaluation	6
Episcissors-60 for Mediolateral Episiotomy: Evaluation of Clinical and Economic Evidence to Inform NICE Medical Technologies Guidance	6
Economic Evaluation of Evusheld for Preexposure Prevention of COVID-19 in High-Risk Populations: Early Evidence from Thailand	6
The Impact of Suboxone’s Market Exclusivity on Cost of Opioid Use Disorder Treatment	6
Exploratory Approach to Incorporating Carbon Footprint in Health Technology Assessment (HTA) Modelling: Cost-Effectiveness Analysis of Health Interventions in the United Kingdom	6
The Hidden Toll of Psychological Distress in Australian Adults and Its Impact on Health-Related Quality of Life Measured as Health State Utilities	6

Cost Effectiveness of Molecular Diagnostic Testing Algorithms for the Treatment Selection of Frontline Ibrutinib for Patients with Chronic Lymphocytic Leukemia in Australia	6
Conditional Funding Recommendations for Drugs in Canada: A Cross-Sectional Analysis	6
Economic Evaluation of Oral Nucleos(t)ide Analogues for Patients with Chronic Hepatitis B in Thailand	6
The Value of New: Consideration of Product Novelty in Health Technology Assessments of Pharmaceuticals	6
Challenges in the Evaluation of Emerging Highly Specialised Technologies: Is There a Role for Living HTA?	6
Budget Impact Analysis of the FreeStyle Libre Flash Continuous Glucose Monitoring System® in Patients with Type 1 Diabetes Mellitus and Type 2 Diabetes Mellitus with Multiple Daily Insulin Injections	6
Comparing Preferences for Disease Profiles: A Discrete Choice Experiment from a US Societal Perspective	5
Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canagliflozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting	5
Prices of Orphan Drugs in Four Western European Countries Before and After Market Exclusivity Expiry: A Cross-Country Comparison of List Prices and Purchase Prices	5
Measurement of Catastrophic Health Expenditure in India: A Systematic Review and Meta-Analysis	5
Exploratory Cost-Utility Analysis of a 37-Gene Panel Versus Usual Care to Guide Therapy for Patients with Intermediate-Risk Myeloid Malignancies	5
Comparison of the Measurement Properties of EQ-5D-5L and SF-6Dv2 in COVID-19 Patients in China	5
Cost of Carbon in the Total Cost of Healthcare Procedures: A Methodological Challenge	5
Quality-Adjusted Life Expectancy Norms Based on the EQ-5D-5L and SF-6Dv2 for China	5
Economic Epidemiology: A Framework to Study Interactions of Epidemics and the Economy	5
The Impact of the Approach to Accounting for Age and Sex in Economic Models on Predicted Quality-Adjusted Life-Years	5
Sedaconda ACD-S for Sedation with Volatile Anaesthetics in Intensive Care: A NICE Medical Technologies Guidance	5
Correction to: The False Economy of Seeking to Eliminate Delayed Transfers of Care: Some Lessons from Queueing Theory	5
Use of Cost-Effectiveness Thresholds in Healthcare Public Policy: Progress and Challenges	4
A Guideline-Implementation Intervention to Improve the Management of Low Back Pain in Primary Care: A Difference-in-Difference-in-Differences Analysis	4
Analysing the Efficiency of Health Systems: A Systematic Review of the Literature	4
Economic Consequences of Anti-HCV Treatment of Patients Diagnosed Through Screening in Italy: A Prospective Modelling Analysis	4
The Inflation Reduction Act: Hope for Prescription Drug Prices in the USA	4
10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?	4
The Effect of Price Changes and Teaspoon Labelling on Intention to Purchase Sugar-Sweetened Beverages: A Discrete Choice Experiment	4
The Broader Opportunity Costs in the Broader Cost-Effectiveness Analysis Framework	4
Societal Cost of Racial Pneumococcal Disease Disparities in US Adults Aged 50 Years or Older	4
Health Economic Evaluations of Obesity Interventions: Expert Views on How We Can Identify, Interpret, Analyse and Translate Effects	4
The Economic Cost of Rising Non-communicable Diseases in India: A Systematic Literature Review of Methods and Estimates	4
Pricing and Reimbursement of Patent-Protected Medicines: Challenges and Lessons from South-Eastern Europe	4
Pharmaceutical Patents in Europe: Radical Reforms Rather Than Getting Rid?	4
The Development of a New Approach for the Harmonized Multi-Sectoral and Multi-Country Cost Valuation of Services: The PECUNIA Reference Unit Cost (RUC) Templates	4
Productivity Loss and Indirect Costs for Patients Newly Diagnosed with Early- versus Late-Stage Cancer in the USA: A Large-Scale Observational Research Study	4
A Systematic Review of the World’s Largest Government Sponsored Health Insurance Scheme for 500 Million Beneficiaries in India: Pradhan Mantri Jan Arogya Yojana	4
EQ-5D-5L Population Norms for Italy	4
Forecasting the Incremental Value to Society Created by a Class of New Prescription Drugs: A Proposed Methodology and Its Application to Treating Chronic Hepatitis C in India	3
Assessing the Value of New Antimicrobials: Evaluations of Cefiderocol and Ceftazidime-Avibactam to Inform Delinked Payments by the NHS in England	3
Evolving Evidence-Based Value Assessment of One-Time Therapies: Tisagenlecleucel as a Case Study	3
Treatment Preferences of Adolescents and Young Adults with Depressive Symptoms: A Discrete Choice Experiment	3
A Multi-dimensional Framework of Valued Output for Primary Care in England	3
Local Level Economic Evaluation: What is it? What is its Value? Is it Sustainable?	3
Avoiding Opportunity Cost Neglect in Cost-Effectiveness Analysis for Health Technology Assessment	3
Correction to: Cost Effectiveness of Allogeneic Umbilical Cord Blood-Derived Mesenchymal Stem Cells in Patients with Knee Osteoarthritis	3
Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options	3
Cost-effectiveness Analysis of the Dental RECUR Pragmatic Randomized Controlled Trial: Evaluating a Goal-oriented Talking Intervention to Prevent Reoccurrence of Dental Caries in Children	3
A Case Study on Reviewing Specialist Services Commissioning in Wales: TAVI for Severe Aortic Stenosis	3
The Short Form 6 Dimensions (SF-6D): Development and Evolution	3
Informing Structural Assumptions for Three State Oncology Cost-Effectiveness Models through Model Efficiency and Fit	3
The Impact of Raising Alcohol Taxes on Government Tax Revenue: Insights from Five European Countries	3
VOLY: The Monetary Value of a Life-Year at the End of Patients’ Lives	3
Authors’ Reply to Sprengholz and Betsch: “Willingness to Pay for a COVID-19 Vaccine”	3
Consumers' Preferences and Willingness to Pay for Personalised Nutrition	3
Financing Comprehensive Immunization Services in Lao PDR: A Fiscal Space Analysis From a Public Policy Perspective	3
Population-Level Impact of Omitting Axillary Lymph Node Dissection in Early Breast Cancer Women: Evidence from an Economic Evaluation in Germany	3
Economic Evaluation of Triple Therapy with Budesonide/Glycopyrrolate/Formoterol Fumarate for the Treatment of Moderate to Very Severe Chronic Obstructive Pulmonary Disease in China Using a Semi-Markov	3
Cost Effectiveness of Pharmacological Management for Osteoarthritis: A Systematic Review	3
What Interventions are Cost Effective in Reducing Violence Against Women? A Scoping Review	3
Evaluating the Cost-Effectiveness of Etranacogene Dezaparvovec Gene Therapy for Hemophilia B Treatment in the USA	3
How is Value Defined in Molecular Testing in Cancer? A Scoping Review	3
Child–Parent Agreement in the Assessment of Health-Related Quality of Life Using the CHU9D and the PedsQLTM	3
Health technology assessment – an important opportunity to inform the use of medical devices in the paediatric population: an analysis of NICE Medical Technology Guidance	3
Is Using Sodium-Glucose Cotransporter-2 Inhibitors to Treat Adults with Chronic Heart Failure Cost-Effective? A Systematic Review of Cost-Effectiveness Studies	3
Cost-Effectiveness Analysis of Temocillin Treatment in Patients with Febrile UTI Accounting for the Emergence of Antibiotic Resistance	3
ENTIMOS: A Discrete Event Simulation Model for Maximising Efficiency of Infusion Suites in Centres Treating Multiple Sclerosis Patients	3
Exploring EQ-5D-Y-3L Experience-Based VAS Values Derived Among Adolescents	3
Avoiding Trouble Ahead: Lessons Learned and Suggestions for Economic Evaluations of COVID-19 Vaccines	2
Correction: Systematic Literature Review of Access Pathways to Drugs for Patients with Rare Diseases	2
The Limitations and Potentials of Evaluating Economic Aspects of Community-Based Health Promotion: A Critical Review	2
Public Preference for Off-Label Use of Drugs for Cancer Treatment and Relative Importance of Associated Adverse Events: A Discrete Choice Experiment and Best-Worst Scaling	2
A Systematic Review of Kidney Transplantation Decision Modelling Studies	2
Determining What Represents Value in the Treatment of Refractory or Unexplained Chronic Cough from the Perspective of Key Stakeholders in Spain Using Multi-Criteria Decision Analysis	2
The Sandbox Approach and its Potential for Use in Health Technology Assessment: A Literature Review	2
Drug Repurposing of Generic Drugs: Challenges and the Potential Role for Government	2
Correction: Exploring the Integration of Environmental Impacts in the Cost Analysis of the Pilot MEL-SELF Trial of Patient-Led Melanoma Surveillance	2
Are Web-Based Valuation Surveys for Preference-Based Measures as Reliable as Face-to-Face Surveys? TTO, DCE and DCE with Duration	2
Different Frameworks, Similar Results? Head-to-Head Comparison of the Generic Preference-Based Health-Outcome Measures CS-Base and EQ-5D-5L	2
Headroom Analysis for Early Economic Evaluation: A Systematic Review	2
How Far is Germany From Value-Based Pricing 10 Years After the Introduction of AMNOG?	2
Beyond the Diagnosis: Valuing Genome-Wide Sequencing for Rare Disease Diagnosis Using Contingent Valuation	2
An Economic Evaluation of Government-Funded COVID-19 Testing in Australia	2

Willingness to Pay for One Additional Quality Adjusted Life Year: A Population Based Survey from China	2
Economic Evaluation Evidence for Resource-Allocation Decision Making: Bridging the Gap for Local Decision Makers Using English Case Studies	2
The False Economy of Seeking to Eliminate Delayed Transfers of Care: Some Lessons from Queueing Theory	2
Evaluating Health Inequality in Five Caribbean Basin Countries Using EQ-5D-5L	2
A Head-On Comparison of EQ-VT- and Crosswalk-Based EQ-5D-5L Value Sets	2
Estimating a Drug’s Price After Loss of Exclusivity as a Function of Its Cost of Goods Sold	2
From Spreadsheets to Script: Experiences From Converting a Scottish Cardiovascular Disease Policy Model into R	2